Research
Hormonal
Setmelanotide (MC4R agonist) is effective in reducing hunger and BMI in patients with HO due to hypothalamic injury, particularly those with specific genetic defects or structural damage affecting the melanocortin pathway.
Setmelanotide is a promising new treatment for HO that targets the root cause (MC4R deficiency). It requires daily injections and may cause skin darkening, but it is one of the few treatments showing efficacy in reducing BMI in this specific population.
ModerateSupportsMEDIUM confidence
Most recently, setmelanotide has also been shown to be effective in reducing hunger and BMI in patients with HO due to hypothalamic injury (NCT04725240)... and so could represent a new treatment opportunity.
Why this rating
Based on Phase 2 open-label data and approval for genetic forms, but HO-specific Phase 3 is ongoing.
Source
Acquired hypothalamic obesity: A clinical overview and update
Christian L. Roth et al. · Diabetes Obesity and Metabolism · 2024
DOI 10.1111/dom.15530
narrative_reviewCited 32×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Acquired hypothalamic obesity (HO) is driven by structural damage to medial hypothalamic nuclei (ARC, PVN), leading to hyperphagia, central insulin/leptin resistance, and reduced sympathetic energy expenditure, resulting in rapid, treatment-resistant weight gain.Good
- GLP-1 receptor agonists (specifically exenatide) reduce fat mass and energy intake in HO patients but do not significantly alter BMI compared to placebo in the short term, and may decrease total energy expenditure.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →